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Mdm2 and MdmX are structurally related p53-binding proteins that function as critical negative regulators
of p53 activity in embryonic and adult tissue. The overexpression of Mdm2 or MdmX inhibits p53 tumor
suppressor functions in vitro, and the amplification ofMdm2 orMdmX is observed in human cancers retaining
wild-type p53. We now demonstrate a surprising role for MdmX in suppressing tumorigenesis that is distinct
from its oncogenic ability to inhibit p53. The deletion of MdmX induces multipolar mitotic spindle formation
and the loss of chromosomes from hyperploid p53-null cells. This reduction in chromosome number, not
observed in p53-null cells with Mdm2 deleted, correlates with increased cell proliferation and the spontaneous
transformation of MdmX/p53-null mouse embryonic fibroblasts in vitro and with an increased rate of spon-
taneous tumorigenesis in MdmX/p53-null mice in vivo. These results indicate that MdmX has a p53-indepen-
dent role in suppressing oncogenic cell transformation, proliferation, and tumorigenesis by promoting cen-
trosome clustering and bipolar mitosis.
Although genetic and biochemical studies clearly indicate
that Mdm2 and MdmX are key regulators of p53 activity, there
are distinct differences in their mechanisms of p53 inhibition.
Mdm2 forms a complex with p53 and functions as an E3 ligase
to target p53 for ubiquitination and proteosomal degradation
(16, 18, 25), thereby inhibiting p53’s transactivation of genes
whose products are involved in the regulation of cell growth
and apoptosis (47). MdmX complexes with p53 and inhibits
p53 transactivation without altering p53 stability (11, 46), and
in contrast to that of Mdm2, MdmX expression is not regulated
by p53. Regardless of these differences, Mdm2 and MdmX act
as critical negative regulators of p53 function in development.
The developmental block imposed by the loss of Mdm2 or
MdmX can be relieved by the deletion of p53 (9, 21, 28, 30, 32)
or by Mdm2 amplification (20, 22) or, in the case of MdmX,
partially rescued by the deletion of the p53 downstream effec-
tor p21 (43). These data indicate that the primary role of
Mdm2 or MdmX in development is to regulate p53.
The amplification and overexpression of either Mdm2 (31) or
MdmX (7, 36) have been observed in a variety of human cancers,
including sarcoma, glioma, and, in the case of MdmX, retinoblas-
toma (24), suggesting that either Mdm2 or MdmX can function as
an oncogene to inhibit p53 activity and promote tumorigenesis.
Since many of these Mdm-overexpressing tumors retain wild-type
p53 alleles, the reactivation of p53 by small-molecule inhibition of
the Mdm2-p53 or MdmX-p53 interaction is an attractive strategy
for treating these cancers (26, 27).
The results of experiments in vitro or in vivo involving the
forced overexpression of Mdm proteins suggest that Mdm2
and MdmX may also have p53-independent roles in promoting
cell growth (13, 23, 29, 38, 41). However, molecular targets for
Mdm2 or MdmX activity other than p53 have yet to be con-
firmed. Furthermore, it remains unclear if physiologic levels of
either Mdm2 or MdmX expression can exert functions that are
distinct from their abilities to downregulate p53 activity. We
have previously characterized mice and primary mouse embry-
onic fibroblasts (MEFs) with p53 or both Mdm2 and p53 de-
leted. These cells display equivalent rates of cell proliferation
and cell transformation in culture, and Mdm2/p53 double null
mice and p53-null mice present with the same rate and tissue
spectrum of spontaneous tumor formation (22), indicating that
normal cellular levels of Mdm2 function primarily to regulate
p53 activity. In contrast, MEFs generated from Mdm2-trans-
genic mice with intact MdmX proliferated slower than MEFs
lacking MdmX (42), suggesting that MdmX might have anti-
proliferative properties when p53 functions are inhibited. To
determine if physiologic levels of MdmX can regulate cell
proliferation in a p53-independent manner, we have generated
and analyzed the growth and transformation of MEFs derived
from mice with p53 or both p53 and MdmX deleted. Unlike our
previous results with Mdm2, the deletion of MdmX increases
the spontaneous transformation and proliferation of immor-
talized p53-null MEFs. Also, in contrast to what occurs with
Mdm2, the loss of MdmX seems to have a profound impact on
chromosome stability. Although both Mdm2/p53 double null
cells and MdmX/p53 double null cells initially display the chro-
mosomal hyperploidy characteristic of p53-null cells, MdmX-
deficient cells undergo a reduction in chromosome number
that correlates with increased cell proliferation and transfor-
mation during their growth in culture. Furthermore, MdmX/
p53 double null mice display increased rates of spontaneous
tumorigenesis relative to those of p53-null mice. Similarly to
MEFs, tumor cells isolated from MdmX/p53-null mice prolif-
erate faster and have fewer chromosomes than p53-null tumor
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cells, corroborating the role for MdmX in the maintenance of
genome stability. Hyperploid, p53-deficient MEFs and tumor
cells that lack MdmX display reduced centrosome clustering
and high levels of multipolar mitotic spindle formations, likely
accounting for the aberrant chromosome segregation and loss
of chromosomes during mitosis. The reintroduction of MdmX
into MdmX/p53-null tumor cells increased the ploidy, reduced
the incidence of multipolar spindles, and decreased the prolif-
eration rate in these cells. These data reveal that MdmX has a
p53-independent role in suppressing cell proliferation, trans-
formation, and tumorigenesis by promoting bipolar mitosis
and preventing chromosome loss in polyploid p53-deficient
cells.
MATERIALS AND METHODS
Cells and cell culture. MEFs were isolated from 13.5-day-old embryos deriving
from crosses between MdmX/ p53/ mice and MdmX/ p53/ mice.
Primary tumor cells were isolated from the thymic tumors of MdmX/ p53/
mice or p53/ mice, and genotyping was performed by PCR. The MdmX mouse
model used in this study, which was previously generated by gene trapping (9),
does not generate an MdmX protein (28), and thus is a presumptive MdmX-null
model. All cells were grown at 37°C with 5% CO2 in Dulbecco’s modified Eagle
medium supplemented with 10% serum, penicillin, and streptomycin. For the
proliferation assay, cells were plated at the density of 1  104/cm2. Results are
from triplicate cultures of two independent cell lines of each genotype (for
MdmX/p53-null and p53-null) or one cell line (for the wild type). For the
immortalization assay, cells were plated at a density of 5.5  104/cm2 on three
10-cm plates and were harvested every third day, counted, and replated under
the same conditions. The accumulated population doubling level (PDL) at a
given passage represents the sum of the PDLs from all previous passages [PDL 
log(nf/n0)/log2, where n0 is the initial number of cells and nf is the final number
of cells]. For the colony formation assay, cells were plated at a low density (200
cells per cm2) and grown for 2 weeks in medium that was changed every 3 days.
Cells were fixed with methanol and stained with crystal violet to evaluate colony
formation. For the transformation assay (focus formation assay), 2  104 cells
per cm2 were grown in Dulbecco’s modified Eagle medium with 7% serum. The
medium was changed every 3 days. After 14 days, the cells were fixed with
methanol and stained with Giemsa stain. For the transfection, cells were trans-
fected with an MDMX expression construct and/or with the puromycin expres-
sion construct pBABE-Puro at a 5:1 molar ratio by use of Lipofectamine 2000
(Invitrogen) in a six-well plate format. Cells were replated 24 h after transfection
and selected for puromycin resistance. MdmX expression was confirmed by
reverse transcriptase PCR (data not shown).
FACS analysis of DNA content. For fluorescence-activated cell sorting (FACS)
analysis, cells were plated at the density of 1  104/cm2 and grown asynchro-
nously to 90% confluence. The cells were fixed in ethanol, stained with pro-
pidium iodide, and analyzed by a Becton Dickinson FACScan flow cytometer
(Mountain View, CA) for DNA content. FACS profiles of wild-type MEFs were
generated in parallel as controls for diploid-cell DNA content.
Metaphase spreads and chromosome counting. Proliferating cells were incu-
bated with colcemid (0.02 g/ml medium) for 90 min, harvested and incubated
in hypotonic solution (0.075 M KCl) for 15 min at 37°C, and fixed with methanol-
acetic acid. Drops of cell suspension were placed on microscope slides, dried,
DAPI (4-6-diamidino-2-phenylindole) stained, and analyzed by fluorescence
microscopy.
Immunofluorescence microscopy. Cells were grown on glass coverslips, fixed in
methanol, and stained with mouse monoclonal -tubulin (Sigma-Aldrich, St.
Louis, MO) and rabbit polyclonal anti-	-tubulin (Sigma-Aldrich) primary anti-
bodies, as well as secondary antibodies coupled to Alexa 488 or Alexa 594
(Molecular Probes). DNA was stained with DAPI. Immunofluorescence images
were recorded using a charge-coupled-device camera attached to an epifluores-
cence Zeiss Axioplan 2 microscope (Zeiss, Thorwood, NY). Single images were
acquired using Metamorph imaging software (Universal Imaging, Downingtown,
PA).
Animal studies. MdmX/ p53/ mice were intercrossed to generate p53-
deficient mice that were MdmX wild type, MdmX heterozygous, or MdmX null.
Cohorts of these mice were monitored for tumor formation as previously de-
scribed (43). Necropsies were performed on mice bearing obvious tumors, and
tumors were harvested and fixed in 10% phosphate-buffered formalin for histo-
logical analysis. The pathological analysis of tumors arising in the mice was
performed by IDEXX (Grafton, MA). Statistical analyses of the rate of tumor
formation was performed using Student’s t test, with a P value of 
0.05 consid-
ered significant. Animals were used in accordance with regulations established by
the University of Massachusetts Medical School’s Institute for Animal Care and
Use Committee and with federal guidelines.
RESULTS
The loss of MdmX increases the growth potential of p53-
null MEFs. To analyze the growth characteristics of p53-null
MEFs in the presence or absence of MdmX, MEFs were gen-
erated from embryos obtained from crosses between
MdmX/ p53/ and MdmX/ p53/ mice harvested at
embryonic day 13.5. In keeping with an earlier report indicat-
ing that the growth rate of p53-null MEFs was not altered by
the deletion of MdmX (28), we found that early-passage p53-
null and MdmX/p53-null MEFs exhibited similar rates of cell
proliferation (Fig. 1A, left panel). However, an increase in the
growth rate of the double null MEFs was observed repeatedly
following serial passage of the primary cells (Fig. 1A, right
panel).
This finding prompted us to compare long-term growth
characteristics of these cells under the standard conditions of
an immortalization assay (15) (Fig. 1B). As expected, the con-
trol wild-type MEFs entered senescence around passage 7 and
failed to immortalize. In contrast, all p53-deficient cell lines
immortalized and continued to divide throughout the course of
the assay. However, there was a striking difference in the
growth patterns of p53-null and MdmX/p53-null MEFs at
higher passages. After passage 7, the loss of MdmX conferred
a distinct growth advantage to p53-deficient cells. Calculation
of the accumulated PDLs (Fig. 1B, right panel) revealed that,
by passage 17, the MdmX/p53-null cells had undergone almost
10 more doublings than the p53-null cells, and the deletion of
MdmX allowed p53-deficient cells to proliferate much faster
and reach drastically higher saturation densities (Fig. 1C). The
estimated population doubling time from the proliferation
curve in Fig. 1C is 15 h for MdmX/p53-null cells versus 23 h for
p53-null cells, and the estimated number of times the popula-
tion doubled from day 1 to day 3 is 2.9 for MdmX/p53-null cells
versus 2.1 for p53-null cells (see Table S1 in the supplemental
material).
The increased growth capacity of p53-null cells relative to
that of wild-type cells is also reflected in their ability to grow
when plated at a low cell density (15). However, p53-null cells
with MdmX deleted not only retain the same plating efficiency
and ability to grow at a low density (see Table S1 in the
supplemental material) but also form much larger colonies
than p53-null cells with intact MdmX (Fig. 1D). Eighty percent
of all MdmX/p53 double null colonies exceeded 200 cells per
colony at day 5 postplating, whereas only 30% of the p53-null
colonies reached this size. These data further demonstrate an
increase in the rate of p53 colony proliferation when MdmX is
deleted. The ability of the MdmX/p53-null cells to reach a
much higher saturation density than the p53-null cells (Fig. 1C)
suggested that the loss of MdmX further compromises the
regulation of cell growth and might induce the transformation
of immortalized p53-deficient cells. Therefore, we performed a
cell transformation assay by allowing the MEFs to grow to
saturation density and assaying for the formation of trans-
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formed foci at 2 weeks postplating. Primary cells deficient for
p53 do not form foci under these conditions, unless they are
transduced with an activated oncogene such as ras (10). How-
ever, the results of the transformation assay (Fig. 1E) revealed
that MdmX/p53-null cells formed numerous foci in culture.
Counts of triplicate 10-cm plates of MdmX/p53-null cells doc-
umented 188 (53 standard deviations) foci larger than 1 mm
in diameter per plate. In contrast, p53-null MEFs did not form
any foci in culture. These results confirm that MdmX inhibits
the spontaneous transformation of immortalized p53-deficient
cells.
MdmX suppresses chromosome loss in p53-null cells. To
investigate the possible effects of MdmX on genome stability,
we compared the cell ploidy, measured as the DNA content
per cell, of propidium iodide-stained p53-null cells with that of
MdmX/p53-null cells at different passages using wild-type
MEFs at passage 2 as a diploid control (Fig. 2A). Very low
passage number (passage 2) MEFs with either p53 or both
MdmX and p53 deleted displayed normal, diploid FACS pro-
files similar to that of the wild-type MEFs. It was reported
previously (6, 12, 15) that MEFs with inactivated p53 genes are
genetically unstable and contain supernumerary chromosome
FIG. 1. The loss of MdmX increases the growth potential of p53-null cells in culture. (A) At passage 4 (Pass 4), growth rates of p53-null and
MdmX/p53-null cells are equivalent and much higher than that of wild-type (WT) cells. At passage 9, MdmX/p53-null cells proliferate faster than
p53-null cells. Error bars represent standard errors of the mean from two independent cell lines. (B) The loss of MdmX confers a growth advantage
to p53-deficient cells during long-term growth in culture. A 3T3 immortalization assay was performed with two or three cell lines of each genotype.
The actual cell number at each passage (left panel) and accumulated PDLs (right panel) are shown. By passage 17, MdmX/p53-null populations
underwent almost 10 more doublings than the p53-null population. PD, number of population doublings. (C) The loss of MdmX allows
immortalized p53-deficient cells to proliferate much faster and to reach much higher saturation densities than the wild-type cells. A proliferation
assay was performed with passage 17 immortalized cells. (D) The loss of MdmX stimulates growth within the individual clones at a low plating
density. Colony formation was evaluated for crystal violet-stained cells at passage 18. (E) The loss of MdmX triggers the spontaneous transfor-
mation of p53-deficient cells. In contrast to p53-null cells, which failed to form foci, MdmX/p53-null cells formed numerous dark-blue foci on
Giemsa-stained plates. Counts of triplicate 10-cm plates revealed 188  53 foci larger than 1 mm in diameter per plate.
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numbers after repeated passages in culture. Indeed, at passage 9,
both MdmX/p53-null MEFs and p53-null MEFs displayed very
small 2N cell subpopulations, and the majority of the cells had 4N
or 4N DNA content. However, while the p53-null cells main-
tained a significant hyperploid subpopulation for more than 20
additional passages, MEFs with both MdmX and p53 deleted
underwent a drastic reduction in ploidy at higher passages.
To confirm that the difference in DNA content reflects dif-
ferences in chromosome numbers, mitotic spreads were pre-
pared from multiple lines of MEFs at low and high passage
numbers, and chromosome numbers per cell were determined
in DAPI-stained spreads (Fig. 2B). Wild-type MEFs at a low
passage number contained mostly diploid numbers of chromo-
somes (n  40), whereas MEFs lacking p53 showed supernu-
FIG. 2. MdmX suppresses the reduction in ploidy and loss of chromosomes in immortalized p53-null cells. (A) Flow cytometry profiles of
PI-stained MEFs. Histograms of DNA content in MdmX/p53-null cells (second row, red) and in p53-null cells (third row, red) are overlayered with
a histogram of passage 2 (p2) wild-type (WT) MEFs (blue) shown as a diploid control. At passage 9, the majority of the cells of both genotypes
show 4N or 4N DNA content. While p53-null cells maintain hyperploid DNA contents at high passage numbers, MdmX/p53 double null cells
display drastic reductions in hyperploid subpopulations at high passage numbers. (B) Chromosome number distribution in low- and high-passage-
number MEFs. For chromosome number determination, chromosomes in at least 50 DAPI-stained metaphase spreads for each cell line and each
passage shown were counted. The deletion of MdmX, but not of Mdm2, caused a drastic reduction in the chromosome number of high-passage-
number p53-null cells. (C) Percentages of cells with greater-than-triploid chromosome contents (more than 60 chromosomes per cell) in
populations of MdmX/p53-null (three cell lines) and p53-null (four cell lines) MEFs. (D) The deletion of MdmX also leads to a reduction in
chromosome numbers in immortalized p21-null cells.
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merary numbers of chromosomes, as expected. This hyper-
ploidy was seen in p53-null MEFs at passages 7 and 8,
regardless of MdmX or Mdm2 status. Wild-type MEFs that
undergo a spontaneous loss of p53 or p19ARF are capable of
spontaneous immortalization (15, 19), and very high passage
number (passage 45) wild-type MEFs displayed hyperploidy,
similar to that observed in p53-null MEFs at passage 23 or in
Mdm2/p53-null MEFs at passage 27, with a large subpopula-
tion of cells containing more than 80 chromosomes per cell. In
contrast, MEFs lacking both p53 and MdmX had far fewer
chromosomes per cell at passage 24 than did p53-null MEFs or
Mdm2/p53 double null MEFs at similar passages. In agree-
ment with the FACS data, chromosome counts from mitotic
spreads from low and high passage numbers clearly revealed
that MdmX/p53-null cells go through the radical reduction in
chromosome number during prolonged growth in culture. The
majority of the MdmX/p53-null cells at passage 24 contained
between 50 and 60 chromosomes, and only a few cells had
more than 70 chromosomes per cell. Similar decreases in
chromosome number were observed in all MdmX/p53-null
lines tested. The results of a statistical analysis of chromo-
some number distribution in populations of high-passage-
number MdmX/p53-null MEFs (three cell lines) and p53-
null MEFs (four cell lines) are shown in Fig. 2C. Almost
60% of the p53-null cells and only 12% of the MdmX/p53-
null cells presented with a greater-than-triploid chromo-
some number.
In contrast to MdmX, the presence or absence of Mdm2
does not seem to affect chromosome numbers of p53-null cells
(Fig. 2B). In order to examine whether the loss of MdmX
affects chromosome number in polyploid cells of a different
background, we examined MEFs previously generated from
MdmX-null mice with the p53 target gene, p21WAF1, deleted
(43). The loss of p21 function in MEFs is known to induce
endoreduplication, resulting in polyploid cells (44). The results
in Fig. 2C show that MdmX/p21 double null MEFs have much
lower chromosome numbers per cell than p21-null MEFs at
similar passage numbers, suggesting that the MdmX-mediated
maintenance of the chromosome number is not unique to
p53-deficient cells.
MdmX suppresses spontaneous tumorigenesis in p53-defi-
cient mice. Spontaneous transformation of p53-null cells in the
absence of MdmX coupled with the increased rate of chromo-
somal loss in the MdmX/p53-null cells prompted us to inves-
tigate whether the antiproliferative growth properties of
MdmX could alter spontaneous tumorigenesis in p53-null
mice. Cohorts of p53-deficient mice that were wild type, het-
erozygous, or null for MdmX were generated, and a tumor
assay was performed. We have previously demonstrated that
Mdm2 status does not affect the onset of tumorigenesis in
p53-deficient mice, and mice with both Mdm2 and p53 deleted
present with the same tumor types as p53-null mice (22). In
contrast, the deletion of one or both MdmX alleles significantly
altered tumor formation in p53-heterozygous or p53-null mice
(Fig. 3A and B). The tumor spectrum and tumor burden of
p53-heterozygous mice or p53-null mice in the presence or
absence of MdmX remained unchanged, with thymic lympho-
mas and sarcomas being the predominant tumor types ob-
served (data not shown); however, the rate of tumorigenesis
was accelerated in the absence of MdmX. Fifty percent of the
p53-null mice present with spontaneous tumors by 25 weeks of
age. On average, mice lacking both p53 and MdmX develop
tumors 5 weeks earlier. These results reveal that MdmX sup-
presses oncogenesis when p53 is deleted and confirm in vivo
that MdmX has a p53-independent role in regulating cell
transformation.
MdmX suppresses proliferation and chromosomal loss in
p53-null tumor cells. To further explore the link between
MdmX and the maintenance of chromosome ploidy, thymic
lymphomas were harvested and cultured from p53-null mice
and from MdmX/p53 double null mice. Interestingly, cells de-
rived from the MdmX/p53 double null tumors proliferated
faster and reached much higher saturation densities than cells
derived from p53-null tumors (Fig. 4A), reminiscent of what
we observed in our studies of immortalized MEFs. Further-
more, FACS analysis and mitotic spreads of these cells at four
to six passages removed from the tumor tissue revealed that
the p53-null tumor cell population had a much larger fraction
of cells with 4N and 4N DNA content and with higher chro-
mosome numbers than the MdmX/p53-null tumor cell popu-
lation (Fig. 4B, upper and middle panels). The presence or
absence of Mdm2 does not seem to have an impact on ploidy
and the chromosome number of MdmX/p53-null tumor cells
(Fig. 4B, bottom panel), indicating that this MdmX function is
both p53 and Mdm2 independent. To confirm that MdmX
could regulate ploidy and the proliferation of these cells, we
FIG. 3. MdmX suppresses tumorigenesis in p53-deficient mice. Co-
horts of mice from the indicated genotypes were monitored for spon-
taneous tumor formation. (A) Kaplan-Meier plot of tumorigenesis in
p53-heterozygous mice that are either wild type or heterozygous for
MdmX. The loss of one functional allele of MdmX accelerates tumor-
igenesis in mice heterozygous for p53. (B) Kaplan-Meier plot of tu-
morigenesis in p53-null mice that are either wild type or null for
MdmX. The loss of MdmX function accelerates tumorigenesis in the
absence of p53. P values are shown for each curve.
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transfected the MdmX/p53-null tumor cells with an expression
vector bearing MdmX. Stable, puromycin-resistant MdmX
transfectants displayed ploidy and proliferation characteristics
similar to those of p53-null tumor cells. Propidium iodide
staining for two of the MdmX-transfected clones (c1 and c2)
shown in Fig. 4C displayed increased DNA contents relative to
those of the control (nontransfected, nonselected) cells and the
mock-transfected (puromycin vector) cells, presumably due to
MdmX-mediated retention of supernumerary chromosomes in
these p53-null cells. Reintroduction of MdmX into the double
null tumor cells drastically slowed the rate of cell proliferation
(Fig. 4D). These data, obtained using tumor-derived cells, con-
firmed our results with MEFs indicating that MdmX prevents
chromosome loss and negatively regulates the proliferation of
p53-null tumor cells.
MdmX inhibits spindle multipolarity in p53-null cells. Most
tumor cells display genomic instability, with aneuploidy arising
due to defects in chromosome segregation during mitosis (35,
45). In many cases, these defects are associated with the hy-
peramplification of centrosomes, leading to the formation of
multipolar spindles (37) and centrosome abnormalities that
correlate with high-grade tumors (8, 33). To explore the mech-
anism by which MdmX regulates chromosome number in the
hyperploid p53-null cells, we performed an immunofluores-
cence analysis of p53-null and MdmX/p53-null MEFs and tu-
mor cells and an analysis of MdmX/p53-null tumor cells ex-
pressing exogenous MdmX. Antibodies against -tubulin and
	-tubulin were used to stain microtubules and centrosomes,
respectively, and DAPI was used to counterstain DNA. MEFs
or tumor cells with p53 deleted clearly showed increased num-
bers of centrosomes, as previously reported (4, 12). Centro-
somes were often clustered around the opposite poles, giving
rise to bipolar spindles and facilitating equal or semiequal
segregations of the supernumerary chromosomes during mito-
sis (Fig. 5A). In sharp contrast, centrosome clustering was very
rare in cells with both MdmX and p53 deleted. Instead, almost
FIG. 4. MdmX suppresses cell proliferation and the loss of chromosomes in p53-null tumor cells. Cells were isolated from the thymic tumors
of p53-null, MdmX/p53-null, and Mdm2/MdmX/p53-null animals. (A) MdmX/p53-null tumor cells proliferate much faster and reach higher
saturation densities than p53-null tumor cells. Error bars represent standard errors of the means from two independent experiments. (B) Double
and triple null tumor cells have reduced ploidy and chromosome numbers compared to those of the p53-null tumor cells. Chromosome number
ranges are the same as in Fig. 2. The results represent the average chromosome numbers from two independent experiments for null and double
null cells and from one experiment for triple-null cells. (C) DNA content of MdmX/p53-null tumor cells transfected with an MdmX-expressing
plasmid. Parental, nontransfected cells (Control), cells transfected with the puromycin vector only (Mock), and stable MdmX transfectants (clones
c1 and c2) were analyzed for DNA content. MdmX-transfected clones showed higher DNA contents than those of both controls. (D) The
reintroduction of MdmX into the double null tumor cells (clones c1 and c2) significantly reduced the rate of cell proliferation.
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one-quarter of the mitotic MdmX/p53 double null cells formed
symmetrical and asymmetrical multipolar spindles (Fig. 5B).
Interestingly, these multipolar spindles permit chromosome
segregation, as telophase figures with more than two groups of
separated chromosomes are frequently observed in these cells
(Fig. 5C). While it is doubtful that these groups contain the
correct diploid chromosome set, some may generate viable
cells, albeit with lower chromosome numbers than parental
cells. Furthermore, when transfected with exogenous MdmX,
MdmX/p53-null tumor cells also displayed increased centro-
some clustering (Fig. 5D) accompanied by a drastic reduction
in the formation of multipolar spindles. Overall, only about
10% of the mitotic cells lacking p53 were found to have mul-
tipolar spindles, whereas on average 23% of the p53-null cells
displayed multipolar spindles when MdmX was absent (Fig.
5E). These data indicate that the presence of MdmX correlates
with centrosomal clustering and reduced multipolar spindle
formation in p53-null MEFs and in cells derived from p53-null
tumors.
DISCUSSION
Our results document a role for MdmX in suppressing cell
transformation and tumorigenesis that is distinct from the well-
established ability of MdmX to negatively regulate p53. Cells
lacking both p53 and MdmX exhibit a higher rate of cell
proliferation and higher saturation density than p53-null
cells after passage in culture, although they are initially equiv-
alent in their rates of proliferation. In addition, MdmX/p53-
null cells form larger colonies when plated at a low density and
display a far greater rate of cell growth in a standard 3T3 cell
immortalization assay than p53-null cells. These findings are in
contrast to what we reported previously for Mdm2, as the
deletion of Mdm2 does not alter the rate of cell proliferation or
immortalization of p53-null MEFs (22). Furthermore, unlike
p53-null cells, MEFs deficient for MdmX and p53 form nu-
merous foci when plated in a cell transformation assay, con-
firming that MdmX suppresses the transformation of immor-
talized p53-null cells. In vivo evidence for a p53-independent
FIG. 5. MdmX suppresses spindle multipolarity in p53-null MEFs and tumor cells. Cells were stained with mouse monoclonal anti--tubulin
(green) antibodies, rabbit polyclonal anti-	-tubulin (red) antibodies, and DAPI (blue). (A) Bipolar spindles in p53-null cells with amplified
centrosomes. More than 30% of the mitotic p53-null MEFs and tumor cells with amplified centrosomes show bipolar spindle assembly. In those
cells, chromosomes are aligned on one metaphase plate and are likely to be distributed equally or almost equally between the two daughter cells,
as evident in the telophase cell (two right-hand sets of images). (B) Multipolar spindles in MdmX/p53-null cells with amplified centrosomes.
Symmetrical (left and middle sets of images) and asymmetrical (right set of images) multipolar spindles are common in MdmX/p53-null cells.
(C) In cells with multipolar spindles, chromosomes can separate and generate telophase figures with more than two groups of chromosomes.
(D) Bipolar spindles in MdmX/p53-null tumor cells transfected with an MdmX-expressing plasmid. (E) The incidence of mitotic cells with
multipolar spindles was evaluated by scoring from 100 to 200 mitotic figures for MEFs (M) and tumor cells (T). The histograms show the averages
(from left to right) for two p53-null MEF lines, two experiments with p53-null tumor cells, three double null MEF lines, two experiments with
double null tumor cells, and two clones of Mdm4-transfected double null tumor cells. Error bars represent standard errors of the means. The loss
of MdmX function causes a more-than-twofold increase in spindle multipolarity. Scale bars  10 m.
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role for MdmX in suppressing transformation is provided by
the results of the tumor studies. Mice deficient for both MdmX
and p53 develop spontaneous tumors much earlier than p53-
null mice. Notably, these differences are not observed in p53-
deficient mice lacking Mdm2 (22). As physiologic levels of
MdmX are not regulated by p53 (39), these data demonstrate
a p53-independent role for native levels of MdmX in tumor
suppression.
MEFs deficient for p53 or for both MdmX and p53 display
supernumerary centrosomes and hyperploidy at low passage
numbers. However, MdmX/p53 double null cells undergo a
loss of chromosomes during growth in culture, and reintroduc-
tion of MdmX into MdmX/p53-null cells increases their ploidy.
This appears to be a unique feature of MdmX, as ploidy in
p53-null cells is not affected by the presence or absence of
Mdm2.
Deletion of MdmX in p53-null cells correlates with an in-
crease in the subpopulation of cells displaying multipolar spin-
dles during mitosis, and the addition of exogenous MdmX to
MdmX/p53 double null cells increases the coalescence of cen-
trosomes and promotes bipolar cell division.
Since Hansemann’s (14) and Boveri’s (2) experiments more
than a century ago, multipolar mitosis and aneuploidy have
been tightly linked to tumorigenesis (35, 45, 48). Centrosomal
clustering and bipolar spindle formation have been suggested
to be critical for preserving the genomic stability of noncancer
cells (34, 37) and for the maintenance and propagation of
hyperploid cells with amplified centrosomes (3, 40). The re-
duction of chromosome numbers observed in polyploid p53-
deficient cells after prolonged culturing in vitro has been pro-
posed to give rise to a more stable, yet aneuploid, karyotype
that confers a growth advantage to a cell (5). This reduction in
ploidy is thought to be analogous to the previously described
genomic convergence during tumor progression in vivo (17),
and the relatively stable karyotypes found in many advanced
tumors and established tumor cell lines may reflect the evolve-
ment of a genotype optimized for growth under specific con-
ditions (1).
The increased spindle multipolarity, chromosomal loss, and
increased proliferation of p53-null cells lacking MdmX indi-
cate a p53-independent role for MdmX in the suppression of
tumorigenesis through the maintenance of genome stability.
As the effect of MdmX loss on the proliferation and ploidy of
p53-null cells is observed only at late passages or in immortal-
ized cells, it is likely that MdmX plays a p53-independent role
in regulating cell transformation and subsequent tumorigene-
sis. Although the presence or absence of MdmX does not seem
to impact the amplification of centrosomes in p53-null cells,
the increase in bipolar spindle polarity and chromosome ploidy
following the reintroduction of MdmX into MdmX/p53-null
cells confirms that MdmX alters the organization of these
supernumerary centrosomes. Therefore, we propose that the
MdmX-mediated clustering of amplified centrosomes facili-
tates bipolar mitosis and the propagation of hyperploid ge-
nomes. The loss of MdmX increases spindle multipolarity and
the rate of chromosomal loss, and the resulting reduction in
ploidy should yield a faster-replicating population of double
null cells. Conversely, chromosomal clustering and the anti-
proliferative effect of exogenous MdmX in p53-null cells sug-
gest that cells with supernumerary chromosomes that undergo
bipolar mitosis proliferate slower than cells with multipolar
spindles and further support a p53-independent role for
MdmX in tumor suppression.
MdmX has recently been recommended as a suitable target
for small-molecule inhibition in the treatment of human can-
cers (24, 46), as the inhibition of the MdmX-p53 interaction in
tumors with wild-type p53 likely releases tumor suppressor p53
activity. However, it is unclear what effect this inhibition has on
p53-independent MdmX activities, especially in the approxi-
mately half of all human tumors that lack functional p53.
Therefore, further work is needed to define the precise mo-
lecular mechanism of the MdmX-mediated suppression of pro-
liferation and tumorigenesis.
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